Formulation Development
TKIS - Next-Generation BCR-ABL TKIs for CML: The Allosteric Era
Emil Kuriakose, MD, explores the current CML treatment landscape, ongoing clinical challenges, and the potential of next-generation TKIs currently in development, offering hope for the growing CML community.
WHITEPAPER - From Service Provider to Strategic Partner
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability.
IPSC-NK THERAPIES - Advancing Allogeneic Platforms: The Future of Scalable iPSC-NK Therapies
Stefan Braam, PhD, explores how developers across the industry are tackling these challenges through process optimization, automation, and gene editing innovations. These efforts aim to deliver robust, cost-effective allogeneic platforms that meet the demands of modern healthcare.
CAR-T CELLS - The Growing Benefits of CAR-T Cells in Cancer Research & Beyond
Michael Kapinsky, PhD, says successful management or even curing a growing range of severe diseases, often lacking sufficient treatment options, seems to be in reach using CAR-engineered immune cells.
NASAL DELIVERY - Blazing a Trail to Patient-Friendly CNS Therapies: Exploring The Promise, Progress & Challenges of Nose-to-Brain Drug Delivery
Justin Lygrisse explores the rationale behind nose-to-brain delivery and the early clinical and preclinical efforts now underway to assess its potential.
Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program
Hongene Biotech Corporation recently announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end…
Single-Cell Multiomics Enables High-Resolution Vector Copy Number Profiling in CAR-T Therapie
Mission Bio, the leader in single-cell multiomics, published research in Molecular Therapy Advances showing that its Tapestri® platform can profile vector copy number (VCN), surface…
Ecolab Life Sciences Opens Bioprocessing Applications Lab in Korea to Support Downstream Process Development Across Asia
Ecolab Life Sciences is expanding the bioprocessing business with the launch of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, giving biopharmaceutical manufacturers across…
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
Achieve Life Sciences, Inc.recently announced significant operational progress including the transfer of cytisinicline manufacturing to U.S.-based Adare Pharma Solutions (Adare). Achieve has now completed the…
Cellares & Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. (Nasdaq:…
Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced the first subject has been dosed in…
Bio-Rad Launches PTC Harmony 96 & PTC Harmony Deepwell Thermal Cyclers
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the PTC…
PTC Therapeutics to Report Results From PIVOT-HD Long-Term Extension Study
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim…
Evonik & Higuchi Strengthen Oral Drug Delivery Innovation in Japan With New Joint Laboratory
Evonik and Higuchi Inc., a leading Japanese trading company in the pharmaceutical sector, are opening a joint laboratory located in Yokohama, Japan. The “Open Pharma…
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced positive topline results…
Evonik Strengthens Biotechnology Capabilities for Drug Substance Manufacturing With New Investment in Slovakia
Evonik is investing around EUR 80 million to expand its biotechnology capabilities at its Fermas site in Slovenská Ľupča, Slovakia. The investment will add state-of-the-art…
MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, recently announced the launch of the…
Crown Bioscience & Turbine Partner to Connect AI-Driven Prediction With Organoid Validation in Translational Oncology
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology…
SPECIAL FEATURE - Bioavailability & Solubility: Experimental Techniques Combined With Computational Decision-Making Rapidly ID the Most Viable Enhancement Pathway
Contributor Cindy H. Dubin highlights other ways formulators are relying on automation, such as Artificial Intelligence and Machine Learning, and how these tools are being combined with experimental confirmation to identify the most promising development strategies.
ARTIFICIAL INTELLIGENCE - The AI-Driven Path to Precision Therapeutics
Rotem Gura-Sadovsky, PhD, and Maayan Eilon-Ashkenazy, PhD, explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.
